TECHNOLOGY LICENSING OPPORTUNITY: AirWave

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

TRIAD - DOE CONTRACTOR

Contract Value

Not provided

Codes & Classification
Solicitation Number

S-167761

NAICS

339113 - Surgical Appliance and Supplies Manufacturing

Classification Code

1240

Additional Details
Set Aside

NONE

Place of Performance

Los Alamos, New Mexico, UNITED STATES

SourceSAM
Documents1
This special notice announces a technology licensing opportunity for "AirWave," an innovative respiratory therapy technology developed at Los Alamos National Laboratory (LANL). The AirWave system leverages personalized, non-invasive sound wave therapy to address the persistent challenge of mucus buildup in the lungs—a critical concern for patients suffering from conditions such as COVID-19, pneumonia, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other chronic lung diseases. Purpose and Scope: The primary objective of this opportunity is to identify commercial partners interested in licensing the AirWave technology for further development and market deployment. AirWave is designed to enhance respiratory care by using gentle, patient-specific sound vibrations to loosen and clear mucus deep within the airways. This approach aims to improve patient outcomes by facilitating easier breathing, reducing complications, and accelerating recovery for individuals with acute or chronic respiratory conditions. Key Features and Deliverables: AirWave distinguishes itself through several advanced features: - Patient-specific customization: Utilizing CT scans and advanced computer modeling, the system determines the optimal sound frequencies tailored to each patient’s unique lung anatomy. - Targeted therapy: The technology can precisely direct vibrations to problem areas within the lungs, maximizing therapeutic effectiveness. - Non-invasive delivery: Therapy is administered either through the mouth or externally via acoustic transducers, speakers, or shakers, eliminating the need for invasive procedures. - Higher efficiency: AirWave employs higher-frequency sound waves than conventional methods, resulting in stronger airway vibrations and more effective mucus clearance. - Versatile application: The technology is adaptable for use in hospitals, pulmonary rehabilitation centers, home healthcare settings, critical care units, and potentially as a complementary therapy alongside pharmaceutical treatments. The expected deliverable for licensees is the commercialization of a scalable, patient-friendly respiratory therapy device or system that can be integrated into a variety of healthcare environments. Contracting Entity and Contact Information: The licensing opportunity is offered by TRIAD, a Department of Energy (DOE) contractor operating at Los Alamos National Laboratory in Los Alamos, New Mexico. The contracting entity is a federal office, and all inquiries regarding licensing should be directed to the LANL Technology Partnerships team. The primary and secondary contacts for this opportunity are Satya Srinivasan and Lindsay Augustyn, both reachable at [email protected]. Relevant Details: - NAICS Code: 339113 (Surgical Appliance and Supplies Manufacturing) - Product Service Code: 1240 - Place of Performance: Los Alamos, New Mexico, United States - Patent Status: Patent pending (Development Status: TRL 3) - Set-Aside: None (open to all qualified entities) - Notice Source: BIDMATCH_SAM (SAM.gov Opportunity ID: d79917ed482a4b58a22f42ec3baf9054) - Additional information and technology details are available at the LANL technology licensing portal. Special Considerations: This notice is not a solicitation for external development services; rather, it is an invitation for companies—both established and start-ups—to engage in licensing discussions for the AirWave technology. LANL’s licensing program offers both exclusive and non-exclusive agreements, supporting the transition of laboratory-developed inventions to commercial products. Interested parties are encouraged to review the technology and contact LANL for further information or to initiate licensing negotiations. Summary: AirWave represents a significant advancement in respiratory therapy, offering a customizable, non-invasive, and highly effective solution for airway clearance. With broad clinical and commercial potential, this technology is positioned to benefit hospitals, device manufacturers, rehabilitation centers, home healthcare providers, and other stakeholders in the respiratory care market. Companies seeking to enhance their product portfolios with cutting-edge, patient-centered innovations are encouraged to consider this licensing opportunity. For further details or to express interest, contact [email protected] or visit the official notice at https://sam.gov/opp/d79917ed482a4b58a22f42ec3baf9054/view.